We demonstrate here that a novel in vivo active cancer immunotherapy based on CH-NP loaded with an adjuvant and antigen to increase in vivo maturation of DCs leads to potent antigen-specific CD8+ T cell immunity after direct injection of such CH-NPs into tumor-bearing mice. This evidence concerns the gene CD8A and cancer.